France’s Haute Autorite de Sante public health body advised the government not to use Valneva’s VLA2001 COVID-19 vaccine as part of its wider vaccination strategy, although two rival products should be included as booster shots.
https://www.pharmalive.com/wp-content/uploads/2021/12/Valneva-says-Chikungunya-vaccine-Phase-3-trial-has-met-primary-endpoint-Reuters-12-21-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-12-08 05:29:292022-12-08 11:08:06French health authority advises against use of Valneva’s COVID-19 vaccine
